GenScript ProBio (Biopharma, Pharmaceutical) — Funding, Investors & Signals 2026

GenScript ProBio

A comprehensive R&D and production platform offering complete solutions for cell and gene therapy, vaccine discovery, and antibody protein drugs.

Founded 2002 1001-5000 employees Series C Total: $220.00M Biopharma, Pharmaceutical

GenScript ProBio, a leading biopharmaceutical R&D and production platform, offers comprehensive solutions for cell and gene therapy, vaccine discovery, and antibody protein drugs. Established in 2002, the company has made significant strides in the Biopharma and Pharmaceutical industries. In its latest funding round, the company secured an impressive $220.00M Series C investment on 18 January 2023. Notably, this round saw participation from a diverse group of investors including HighLight Capital, New Alliance Capital, Legend Capital, GF Xinde, Hillhouse Investment, 兴业资产管理股份有限公司, Huatai Zijin Investment, and Xiamen C&D Corporation. GenScript ProBio's comprehensive range of services, encompassing end-to-end support for cell and gene therapy drugs, vaccine and biopharmaceutical discovery, and antibody protein drugs, positions the company as a significant player in the biopharmaceutical space. With a strong track record and support from notable investors, the company is well-positioned to continue its growth and innovation in the burgeoning field of biopharmaceuticals.

Funding Stage	Amount	Investors	Lead Investors	Date
Series C	••••••	8	•••• ••••	18 Jan 2023

Funding Stage

Amount

Investors

Lead Investors

Date

Series C

••••••

•••• ••••

18 Jan 2023

FAQ About GenScript ProBio

A comprehensive R&D and production platform offering complete solutions for cell and gene therapy, vaccine discovery, and antibody protein drugs.

GenScript ProBio was founded in 2002.

GenScript ProBio operates in the following industries: Biopharma, Pharmaceutical.

GenScript ProBio has approximately 1001-5000 employees.

GenScript ProBio has completed 1 funding round, raising a total of $220.00M. The latest funding stage is Series C.

Top alternatives and competitors to GenScript ProBio include Perseus Proteomics Inc., 艾比玛特医药科技(上海)有限公司, Shanghai Junshi Biosciences Co Ltd, WuXi Biologics, ProBio. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.

GenScript ProBio and Perseus Proteomics Inc. are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

GenScript ProBio

General Information

Track GenScript ProBio

Discover More

About GenScript ProBio

Funding Rounds & Investors (1)

Latest News

GenScript ProBio Alternatives & Competitors

FAQ About GenScript ProBio

Don't just browse. Track.